A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Received treatment in Study KGBI and have adequately completed the study treatmentsand last visit of study KGBI, including any applicable systemic AD treatmentwashout.

• For female participants of childbearing potential, highly effective contraceptiveuse should be consistent with local regulations regarding the methods ofcontraception for those participating in clinical studies

Exclusion Criteria:

• Developed an serious adverse events (SAE) during their participation in parent studyKGBI deemed related to lebrikizumab, which in the opinion of the investigator or ofthe medical monitor could indicate that continued treatment with lebrikizumab maypresent an unreasonable risk for the participant.

• Developed an AE during their participation in the study KGBI that was deemed relatedto lebrikizumab and led to study treatment discontinuation, which in the opinion ofthe investigator or of the medical monitor could indicate that continued treatmentwith lebrikizumab may present an unreasonable risk for the participant.

• Met the criteria for permanent study intervention discontinuation in study KGBI, ifdeemed related to lebrikizumab or led to investigator- or sponsor-initiatedwithdrawal of participant from the study (for example, noncompliance, inability tocomplete study assessments, etc.)

Note: If study KGBI is still blinded at the time of rollover to study KGBJ, conditions deemed related to the study treatment will be considered related to lebrikizumab.

• Are pregnant or breastfeeding or are planning to become pregnant or breastfeedduring the study.